FeesSafety
Pluang+

SEALSQ reports 131% revenue growth in H1 2026 but posts $27.8M net loss amid R&D investments

Company Fundamentals
14 Sep 2026, 20:06 WIB
Danny Green
View Source
Neutral
SEALSQ reports 131% revenue growth in H1 2026 but posts $27.8M net loss amid R&D investments

SEALSQ Corp reported a 131% increase in revenue to $11.2 million for H1 2026, driven by strong demand for its secure semiconductor products and services. Despite this growth, the company posted a net loss of $27.8 million due to higher spending on research, development, and product certification. SEALSQ maintains a strong financial position with $486.1 million in cash and low debt. The company reaffirmed its 2026 revenue guidance of $27 million to $36 million, expecting continued growth from its quantum security and semiconductor offerings.

SEALSQ Corp's H1 2026 earnings report is the subject, provided here with Pluang's Technology sector market data for context. Of 150 priced US Technology stocks on Pluang, 80 rose and 67 fell today. Notable price changes include HPE down 10.30%, NOK down 10.18%, and OKTA up 10.09%, as of Sep 14, 2026 21:31 WIB.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
27 minutes ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
27 minutes ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
1 hour ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
1 hour ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App